These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 26973206)

  • 1. Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis.
    Chen LY; Molina-Vila MA; Ruan SY; Su KY; Liao WY; Yu KL; Ho CC; Shih JY; Yu CJ; Yang JC; Rosell R; Yang PC
    Lung Cancer; 2016 Apr; 94():46-53. PubMed ID: 26973206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.
    Kawahara A; Azuma K; Sumi A; Taira T; Nakashima K; Aikawa E; Abe H; Yamaguchi T; Takamori S; Akiba J; Kage M
    Lung Cancer; 2011 Oct; 74(1):35-40. PubMed ID: 21444121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R.
    Ke EE; Zhou Q; Zhang QY; Su J; Chen ZH; Zhang XC; Xu CR; Yang JJ; Tu HY; Yan HH; Zhang YC; Niu FY; Wu YL
    J Thorac Oncol; 2017 Sep; 12(9):1368-1375. PubMed ID: 28576746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma.
    Reckamp KL; Melnikova VO; Karlovich C; Sequist LV; Camidge DR; Wakelee H; Perol M; Oxnard GR; Kosco K; Croucher P; Samuelsz E; Vibat CR; Guerrero S; Geis J; Berz D; Mann E; Matheny S; Rolfe L; Raponi M; Erlander MG; Gadgeel S
    J Thorac Oncol; 2016 Oct; 11(10):1690-700. PubMed ID: 27468937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma epidermal growth factor receptor mutation testing with a chip-based digital PCR system in patients with advanced non-small cell lung cancer.
    Kasahara N; Kenmotsu H; Serizawa M; Umehara R; Ono A; Hisamatsu Y; Wakuda K; Omori S; Nakashima K; Taira T; Naito T; Murakami H; Koh Y; Mori K; Endo M; Nakajima T; Yamada M; Kusuhara M; Takahashi T
    Lung Cancer; 2017 Apr; 106():138-144. PubMed ID: 28285688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The alteration of T790M between 19 del and L858R in NSCLC in the course of EGFR-TKIs therapy: a literature-based pooled analysis.
    Liang H; Pan Z; Wang W; Guo C; Chen D; Zhang J; Zhang Y; Tang S; He J; Liang W;
    J Thorac Dis; 2018 Apr; 10(4):2311-2320. PubMed ID: 29850136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation.
    Fujita Y; Suda K; Kimura H; Matsumoto K; Arao T; Nagai T; Saijo N; Yatabe Y; Mitsudomi T; Nishio K
    J Thorac Oncol; 2012 Nov; 7(11):1640-4. PubMed ID: 22899358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis.
    Sheng M; Wang F; Zhao Y; Li S; Wang X; Shou T; Luo Y; Tang W
    Eur J Clin Pharmacol; 2016 Jan; 72(1):1-11. PubMed ID: 26490356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China.
    Xu J; Jin B; Chu T; Dong X; Yang H; Zhang Y; Wu D; Lou Y; Zhang X; Wang H; Han B
    Lung Cancer; 2016 Jun; 96():87-92. PubMed ID: 27133756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.
    Sacher AG; Paweletz C; Dahlberg SE; Alden RS; O'Connell A; Feeney N; Mach SL; Jänne PA; Oxnard GR
    JAMA Oncol; 2016 Aug; 2(8):1014-22. PubMed ID: 27055085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.
    Chen K; Yu X; Wang H; Huang Z; Xu Y; Gong L; Fan Y
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1179-1187. PubMed ID: 29063948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting outcomes of EGFR-targeted therapy in non-small cell lung cancer patients using pleural effusions samples and peptide nucleic acid probe assay.
    Wang MC; Wang CL; Chen TL; Chang JW; Lu JJ; Chang PY; Chiou CC
    Clin Chem Lab Med; 2017 Oct; 55(12):1979-1986. PubMed ID: 28787267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
    Chung C
    J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients.
    Matsuo N; Azuma K; Sakai K; Hattori S; Kawahara A; Ishii H; Tokito T; Kinoshita T; Yamada K; Nishio K; Hoshino T
    Sci Rep; 2016 Nov; 6():36458. PubMed ID: 27811988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.
    Su KY; Chen HY; Li KC; Kuo ML; Yang JC; Chan WK; Ho BC; Chang GC; Shih JY; Yu SL; Yang PC
    J Clin Oncol; 2012 Feb; 30(4):433-40. PubMed ID: 22215752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Characteristics and Survival Outcomes for Non-Small-Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Double Mutations.
    Peng M; Weng YM; Liu HL; Yang GF; Yao Y; Han G; Song QB
    Biomed Res Int; 2018; 2018():7181368. PubMed ID: 29581983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.
    Rosell R; Molina MA; Costa C; Simonetti S; Gimenez-Capitan A; Bertran-Alamillo J; Mayo C; Moran T; Mendez P; Cardenal F; Isla D; Provencio M; Cobo M; Insa A; Garcia-Campelo R; Reguart N; Majem M; Viteri S; Carcereny E; Porta R; Massuti B; Queralt C; de Aguirre I; Sanchez JM; Sanchez-Ronco M; Mate JL; Ariza A; Benlloch S; Sanchez JJ; Bivona TG; Sawyers CL; Taron M
    Clin Cancer Res; 2011 Mar; 17(5):1160-8. PubMed ID: 21233402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer.
    Hidaka N; Iwama E; Kubo N; Harada T; Miyawaki K; Tanaka K; Okamoto I; Baba E; Akashi K; Sasaki H; Nakanishi Y
    Lung Cancer; 2017 Jun; 108():75-82. PubMed ID: 28625653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly sensitive and noninvasive detection of epidermal growth factor receptor T790M mutation in non-small cell lung cancer.
    He C; Zheng L; Xu Y; Liu M; Li Y; Xu J
    Clin Chim Acta; 2013 Oct; 425():119-24. PubMed ID: 23886554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiplex Ultrasensitive Genotyping of Patients with Non-Small Cell Lung Cancer for Epidermal Growth Factor Receptor (EGFR) Mutations by Means of Picodroplet Digital PCR.
    Watanabe M; Kawaguchi T; Isa SI; Ando M; Tamiya A; Kubo A; Saka H; Takeo S; Adachi H; Tagawa T; Kawashima O; Yamashita M; Kataoka K; Ichinose Y; Takeuchi Y; Watanabe K; Matsumura A; Koh Y
    EBioMedicine; 2017 Jul; 21():86-93. PubMed ID: 28625519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.